Injectable thymus organoids
AssigneeFibrobiologics, Inc.
InventorsHamid KHOJA, Simon GEBREMESKEL, Pete O'HEERON
Life of this patent
Estimating the term…
Abstract
Provided here are thymus organoids, cell compositions, and pharmaceutical formulations thereof. Also provided are methods for using thymus organoids for clinical and non-clinical use.
Claims29
A thymus organoid comprising one or more fibroblasts and/or one or more fibroblast-derived products;
- and
- a) one or more thymic epithelial cells;
- b) one or more thymocytes;
- c) one or more T-cell progenitors;
- or
- (d) a combination of (a), (b), and/or (c);
- and
- wherein the ratio of the one or more fibroblasts to the one or more thymic epithelial cells, the one or more thymocytes, the one or more T-cell progenitors, or a combination thereof is in the range of about 0.0001:1 to 10000:1.
9-12. (canceled)
(canceled)
(canceled)
18-20. (canceled)
(canceled)
24-28. (canceled)
A method of generating a thymus organoid in vitro, the method comprising culturing one or more fibroblasts and/or one or more fibroblast-derived products;
- and
- a) one or more thymic epithelial cells;
- b) one or more thymocytes;
- c) one or more T-cell progenitors;
- or
- (d) a combination of (a), (b), and/or (c);
- and
- in a culture medium, and on a low adhesion surface.
32-35. (canceled)
38-40. (canceled)
A method of regenerating thymus tissue in a subject in need thereof, the method comprising administering to the subject one or more fibroblasts and/or one or more fibroblast-derived products;
- and
- a) one or more thymic epithelial cells;
- b) one or more thymocytes;
- c) one or more T-cell progenitors;
- or
- (d) a combination of (a), (b), and/or (c).
42-45. (canceled)
Dependencies are inferred from the claim text.